Abstract
The gut microbiota of intensive care unit (ICU) patients display extreme dysbiosis, which is associated with increased susceptibility to organ failure, sepsis and septic shock. However, this dysbiosis is hard to be characterized for each patient, owing to the highly dimensional complexity of gut microbiota. We thus tested whether the concept of enterotype can be applied to the gut microbiota of ICU patients, to describe the dysbiosis. We collected 131 fecal samples from a cohort of 64 ICU patients diagnosed with sepsis or septic shock, using 16S rRNA gene sequencing to dissect their gut microbiota compositions. We find that during the development of sepsis or septic shock, as well as various medical treatments, ICU patients always contain two patterns of dysbiotic microbiota named as ICU-enterotypes, which cannot be explained by the individual host properties such as age, gender and body mass index, as well as external stressors such as infection sites and antibiotic use. ICU-enterotype I comprised predominantly Bacteroides and an unclassified genus of family Enterobacteriaceae, while ICU-enterotype II comprised predominantly Enterococcus. Among more critically ill patients with acute physiology and chronic health evaluation (APACHE) II score > 18, samples of septic shock were more likely to present with ICU-enterotype I (p = 0.041). Additionally, ICU-enterotype I was correlated with high serum lactate level (p = 0.007). Therefore, different patterns of dysbiosis are correlated with different clinical outcomes, suggesting that the diagnosis of ICU-enterotypes as an independent clinical index is crucial. For this purpose, the microbial-based human index (MHI) classifier we proposed shows high precision and effectiveness in timely monitoring of ICU-enterotypes of an individual patient. Together, our work serves as the first step toward precision medicine for septic patients based on the gut microbiota profile.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This is a clinical observational study without any medical intervention. The clinical information of the patients were collected retrospectively. This study is approved by the Ethics Committee of the Hospital.
Funding Statement
This work was partially supported by special Fund for Clinical Research of Wu Jieping Medical Foundation (320.6750.18422), Ministry of Science and Technology of the People's Republic of China (2018YFC0910502), National Natural Science Foundation of China (31871334 and 31671374).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The 16S rRNA gene sequencing data are available in the Genome Sequence Archive (GSA) section of National Genomics Data Center (project accession number CRA002354). The codes for selection of taxonomic biomarkers and building of MHI classifier were available in GitHub.
